To the Editor We are concerned that the study by Dr Vigen and colleagues1 has serious flaws in both design and interpretation.
First, Vigen et al1 characterized testosterone treatment as filling a single prescription for any testosterone product and “once initiated, a patient was assumed to have continued treatment ….” This is insufficient for a definition of long-term testosterone therapy, especially when 17.6% received only 1 prescription. Moreover, there were no data on whether patients continued to regularly receive treatment.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.